Nedaplatin enhanced apoptotic effects of ABT-737 in human cancer cells via Mcl-1 inhibition

Zhang,Chong; Li,Yang‑Ling; Weng,Xu; Li,Li‑Yan; Zhou,Ming‑Xian; Zhang,Da‑Yong; Lin,Neng‑Ming

doi:10.3892/ol.2016.5151

Nedaplatin enhanced apoptotic effects of ABT-737 in human cancer cells via Mcl-1 inhibition

Authors:
- Chong Zhang
- Yang‑Ling Li
- Xu Weng
- Li‑Yan Li
- Ming‑Xian Zhou
- Da‑Yong Zhang
- Neng‑Ming Lin
View Affiliations

Affiliations: School of Medicine, Zhejiang University City College, Hangzhou, Zhejiang 310015, P.R. China, Department of Clinical Pharmacy, Hangzhou First People's Hospital, Hangzhou, Zhejiang 310006, P.R. China, The First Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China, Department of Clinical Pharmacology, Affiliated Hangzhou Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China
Published online on: September 20, 2016 https://doi.org/10.3892/ol.2016.5151
Pages: 4195-4202

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Platinum compounds, such as cisplatin, carboplatin, oxaliplatin and nedaplatin, are widely used to treat a number of solid malignancies. Nedaplatin is a second‑generation platinum complex, based on its pronounced anti-cancer activities against several solid tumors being equivalent to that of cisplatin, but with lower nephrotoxicity. In this context, the present study aimed to investigate the potential anti‑cancer effect by combining nedaplatin with ABT‑737. It was found that nedaplatin greatly increased ABT-737-mediated apoptosis in A549 and 95‑D cells, accompanied by enhanced cleavage of poly(ADP‑ribose) polymerase and caspase‑3. In addition, this enhancement was also paralleled by cytochrome c release and dissipation of mitochondrial membrane potential. Additional mechanistic investigations revealed that nedaplatin plus ABT‑737 exerted a synergistic effect on cancer cells through their ability to accelerate the degradation of Mcl‑1. The present study has revealed nedaplatin as a pertinent sensitizer to ABT‑737, which opens up new avenues for this promising BH3‑mimetic molecule in the clinic.

View Figures

View References

1	Shimada M, Itamochi H and Kigawa J: Nedaplatin: A cisplatin derivative in cancer chemotherapy. Cancer Manag Res. 5:67–76. 2013. View Article : Google Scholar : PubMed/NCBI
2	Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S and Ota K: An early phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho. 19:863–869. 1992.(In Japanese). PubMed/NCBI
3	Furuse K, Fukuoka M, Kurita Y, Ariyoshi Y, Niitani H, Yoneda S, Fujii M, Hasegawa K, Nishiwaki Y, Tamura M, et al: A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer. Gan To Kagaku Ryoho. 19:879–884. 1992.(In Japanese). PubMed/NCBI
4	He YF, Ji CS, Hu B, Fan PS, Hu CL, Jiang FS, Chen J, Zhu L, Yao YW and Wang W: A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma. World J Gastroenterol. 19:5910–5916. 2013. View Article : Google Scholar : PubMed/NCBI
5	Jung Y and Lippard SJ: Direct cellular responses to platinum-induced DNA damage. Chem Rev. 107:1387–1407. 2007. View Article : Google Scholar : PubMed/NCBI
6	Yamashita H, Nakagawa K, Tago M, Igaki H, Nakamura N, Shiraishi K, Sasano N and Ohtomo K: Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II–IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: A retrospective study. Dis Esophagus. 19:15–19. 2006. View Article : Google Scholar : PubMed/NCBI
7	Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, et al: Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol. 11:454–460. 2006. View Article : Google Scholar : PubMed/NCBI
8	Takigawa N, Segawa Y, Ueoka H, Kiura K, Tabata M, Shibayama T, Takata I, Miyamoto H, Eguchi K and Harada M: Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer. Cancer Chemother Pharmacol. 46:272–278. 2000. View Article : Google Scholar : PubMed/NCBI
9	Zhou P, Qian L, Kozopas KM and Craig RW: Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 89:630–643. 1997.PubMed/NCBI
10	Kang MH and Reynolds CP: Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
11	Belmar J and Fesik SW: Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther. 145:76–84. 2015. View Article : Google Scholar : PubMed/NCBI
12	Zhang C, Shi J, Mao SY, Xu YS, Zhang D, Feng LY, Zhang B, Yan YY, Wang SC, Pan JP, et al: Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737. J Cell Mol Med. 19:408–417. 2015. View Article : Google Scholar : PubMed/NCBI
13	Yecies D, Carlson NE, Deng J and Letai A: Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 115:3304–3313. 2010. View Article : Google Scholar : PubMed/NCBI
14	Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, et al: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10:375–388. 2006. View Article : Google Scholar : PubMed/NCBI
15	Maurer U, Charvet C, Wagman AS, Dejardin E and Green DR: Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 21:749–760. 2006. View Article : Google Scholar : PubMed/NCBI
16	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
17	Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H, Dong XW, Hu YZ, Lin NM, He QJ and Yang B: Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther. 10:1264–1275. 2011. View Article : Google Scholar : PubMed/NCBI
18	Yonezawa A and Inui K: Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol. 81:563–568. 2011. View Article : Google Scholar : PubMed/NCBI
19	Giaccone G: Clinical perspectives on platinum resistance. Drugs. 59(Suppl 4): S9–S17, S37-S88. 2000. View Article : Google Scholar
20	Piccart MJ, Lamb H and Vermorken JB: Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol. 12:1195–1203. 2001. View Article : Google Scholar : PubMed/NCBI
21	Kuwahara A, Yamamori M, Nishiguchi K, Okuno T, Chayahara N, Miki I, Tamura T, Inokuma T, Takemoto Y, Nakamura T, et al: Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci. 6:305–311. 2009. View Article : Google Scholar : PubMed/NCBI
22	Boulikas T and Vougiouka M: Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep. 11:559–595. 2004.PubMed/NCBI
23	Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C and Poulain L: Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Apoptosis. 18:492–508. 2013. View Article : Google Scholar : PubMed/NCBI
24	Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, Mehal WZ, Inayat I and Flavell RA: Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis. Science. 311:847–851. 2006. View Article : Google Scholar : PubMed/NCBI
25	Martins LM: The serine protease Omi/HtrA2: A second mammalian protein with a Reaper-like function. Cell Death Differ. 9:699–701. 2002. View Article : Google Scholar : PubMed/NCBI
26	Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, et al: Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem. 287:10224–10235. 2012. View Article : Google Scholar : PubMed/NCBI
27	Huang S and Sinicrope FA: BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 68:2944–2951. 2008. View Article : Google Scholar : PubMed/NCBI
28	Yang C, Kaushal V, Shah SV and Kaushal GP: Mcl-1 is downregulated in cisplatin-induced apoptosis and proteasome inhibitors restore Mcl-1 and promote survival in renal tubular epithelial cells. Am J Physiol Renal Physiol. 292:F1710–F1717. 2007. View Article : Google Scholar : PubMed/NCBI